Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Niraparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 0.98 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 11/20 | 0.98 |
| ▸ | PARP3 | Q9Y6F1 | 10/20 | 0.98 |
| ▸ | TNKS | O95271 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.98 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.98 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.98 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.98 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.98 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.98 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.98 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niraparib SCHEMBL567840 | 1.00 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1422061 | 1.00 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1422151 | 0.99 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1421952 | 0.99 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1421875 | 0.99 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL28370623 | 0.98 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3737274 | 0.95 | PARP1 (0.92) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3737277 | 0.95 | PARP1 (0.92) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3740349 | 0.94 | PARP1 (0.91) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3659848 | 0.93 | PARP1 (0.89) | PARP1PARP2PARP3TNKSCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076528-B2 | System and method for diagnosis and treatment | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (US) | 2018-09-18 | — | — | US | claimed |
| EP-3316881-A1 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT | Pop Test Oncology Limited Liability Company (US) | 2018-05-09 | — | — | EP | claimed |
| US-20180117066-A1 | System and Method for Diagnosis and Treatment | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY | 2018-05-03 | — | — | US | claimed |
| US-9861643-B2 | System and method for diagnosis and treatment | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (US) | 2018-01-09 | — | — | US | claimed |
| WO-2017180086-A1 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (US) | 2017-10-19 | — | — | WO | claimed |
| US-20170232005-A1 | System and Method for Diagnosis and Treatment | POP TEST ONCOLOGY LTD LIABILITY COMPANY (US) | 2017-08-17 | — | — | US | claimed |
| US-9636351-B2 | System and method for diagnosis and treatment | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY (US) | 2017-05-02 | — | — | US | claimed |
| US-20160279149-A1 | System and Method for Diagnosis and Treatment | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY | 2016-09-29 | — | — | US | claimed |
| US-20150366882-A1 | System and Method for Diagnosis and Treatment | POP TEST ONCOLOGY LIMITED LIABILITY COMPANY | 2015-12-24 | — | — | US | claimed |
| US-20140235630-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2014-08-21 | — | — | US | claimed |
| WO-2013049581-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-12631620-B2 | Methods of generating organoids for high throughput screening of drugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| EP-4736953-A2 | THERAPEUTIC AGENTS AND METHODS | Pop Test Oncology LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | AGENDIA N V (NL) | 2026-04-23 | — | — | US | disclosed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| EP-2109608-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-12631620-B2 | Methods of generating organoids for high throughput screening of drugs | HGF, UGT1A10, TGFB2 | PARP1 1343/4885PARP2 248/4885PARP3 1547/4885 |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | BRCA1, PARP3, PARP2 | PARP1 4/4885PARP2 3/4885PARP3 2/4885 |
| US-20160279149-A1 | System and Method for Diagnosis and Treatment | NR3C2, NR3C1, AR | PARP1 2958/4885PARP2 2833/4885PARP3 1807/4885 |
| US-20180117066-A1 | System and Method for Diagnosis and Treatment | NR3C2, NR3C1, AR | PARP1 2958/4885PARP2 2833/4885PARP3 1807/4885 |
| US-20140235630-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PLK2, PHKG1, PIK3CA | PARP1 8/4885PARP2 21/4885PARP3 29/4885 |
| US-20170232005-A1 | System and Method for Diagnosis and Treatment | NR3C2, NR3C1, AR | PARP1 2958/4885PARP2 2833/4885PARP3 1807/4885 |
| US-10076528-B2 | System and method for diagnosis and treatment | NR3C2, NR3C1, AR | PARP1 2958/4885PARP2 2833/4885PARP3 1807/4885 |
| US-20150366882-A1 | System and Method for Diagnosis and Treatment | NR3C2, NR3C1, AR | PARP1 2958/4885PARP2 2833/4885PARP3 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.